EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

ATF3 Within the Interferon Signaling Pathway: A Potential Biomarker for Predicting Pathological Response to Neoadjuvant Chemoimmunotherapy

Chao He, Rui Han, Taiming Zhang, Peng Zhong, Daijuan Huang, Conghua Lu, Yimin Zhang, Jianghua Li, Yuwen Deng, Yong He iD

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Chao He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Activating Transcription Factor 3, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chongqing Municipal Bureau of Science and Technology, National Natural Science Foundation of China, Chongqing Technology Innovation and Application Development Special Key Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant chemoimmunotherapy has achieved high downstaging and pathologic response rates in nonsmall‐cell lung cancer (NSCLC), but outcomes vary significantly. Early identification of beneficiaries remains a challenge.

Methods

This study analyzed baseline transcriptomic data from 24 NSCLC patients (9 major pathological response [MPR], 15 nonmajor pathological response [NMPR]) treated with neoadjuvant chemoimmunotherapy, sourced from the GEO database. Molecular analyses and immune infiltration analyses were performed using pathologic response as an endpoint. After identifying the interferon signaling subset NeoIGS, we analyzed the relationship between NeoIGS and immune scores, immune cell infiltration, and immunotherapy efficacy. A key gene in NeoIGS was screened by reveiver operating characteristic curve (ROC) analysis. Subsequently, the expression of the key gene was assessed by immunohistochemistry in 53 NSCLC patients receiving neoadjuvant chemoimmunotherapy.

Results

Interferon signaling pathway expression and CD8+ T‐cell infiltration were higher in the MPR group. NeoIGS predicted pathological response to neoadjuvant chemoimmunotherapy (AUC = 0.926) and also demonstrated predictive value in the ICIs monotherapy cohort. IPS and TIDE scores also confirmed NeoIGS's association with immunotherapy in the TCGA NSCLC dataset. Furthermore, patients with higher NeoIGS scores had more immune cell infiltration and increased expression of ICI targets. ROC analysis identified ATF3 as NeoIGS's key gene. In the clinical cohort, ATF3 outperformed PD‐L1 in predicting pathologic response, with a 90.0% MPR rate in the high‐expression group.

Conclusion

We established that a subset of interferon signaling pathways, NeoIGS, is closely associated with immunotherapy. Among them, ATF3 is the most critical gene that accurately predicts pathological remission in neoadjuvant chemoimmunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyActivating Transcription Factor 3Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsInterferonsImmunotherapyHumansMaleFemaleSignal TransductionMiddle AgedAgedPrognosis

Stichwörter der Autor:innen

ATF3IFN signaling pathwayNSCLCbiomarkerschemoimmunotherapypathological response

Substanzen

Activating Transcription Factor 3Biomarkers, TumorATF3 protein, humanInterferons

Autor:innen und Institutionen

  • Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Respiratory Disease, Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, China.
  • Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Pathology, Daping Hospital, Army Medical University, Chongqing, China.

ORCID-Profile: Yong He

Förderung

  • Chongqing Municipal Bureau of Science and Technology
  • National Natural Science Foundation of China
  • Chongqing Technology Innovation and Application Development Special Key Project

Zitieren

APA

He, C., Han, R., Zhang, T., Zhong, P., Huang, D., Lu, C., Zhang, Y., Li, J., Deng, Y., & He, Y. (2025). ATF3 Within the Interferon Signaling Pathway: A Potential Biomarker for Predicting Pathological Response to Neoadjuvant Chemoimmunotherapy. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70056

Vancouver

He C, Han R, Zhang T, Zhong P, Huang D, Lu C, et al. ATF3 Within the Interferon Signaling Pathway: A Potential Biomarker for Predicting Pathological Response to Neoadjuvant Chemoimmunotherapy. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70056

BibTeX
@article{He2025,
  author = {He, Chao and Han, Rui and Zhang, Taiming and Zhong, Peng and Huang, Daijuan and Lu, Conghua and Zhang, Yimin and Li, Jianghua and Deng, Yuwen and He, Yong},
  title = {ATF3 Within the Interferon Signaling Pathway: A Potential Biomarker for Predicting Pathological Response to Neoadjuvant Chemoimmunotherapy},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70056}
}
Kostenlos starten →